Newsome SD, et al. A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis. Abstract 60. ECTRIMS 11-13 sept 2019, Stockholm, Zweden.
Lixisenatide bij vroege Parkinson: minder progressie van motorische beperkingen
jun 2024 | Bewegingsstoornissen